CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −1,725 | $88.37 | $152K | 97,994 |
| 2026-07-01 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 352,357 | ||
| 2026-07-01 | Sloan Sheldon Chief Medical Officer | Option exercise 10b5-1 | +8,334 | $27.46 | $229K | 8,334 |
| 2026-07-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −6,500 | $87.52 | $569K | 1,834 |
| 2026-07-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −1,834 | $88.34 | $162K | 0 |
| 2026-07-01 | Sloan Sheldon Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,334 | 305,000 | ||
| 2026-07-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −10,176 | $87.44 | $890K | 587,364 |
| 2026-07-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −4,234 | $88.12 | $373K | 583,130 |
| 2026-07-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −590 | $88.91 | $52K | 582,540 |
| 2026-06-25 | Burrows Scott L Chief Financial Officer | Option exercise | +15,000 | $14.50 | $218K | 112,994 |
| 2026-06-25 | Burrows Scott L Chief Financial Officer | Sale | −5,000 | $87.12 | $436K | 107,994 |
| 2026-06-25 | Burrows Scott L Chief Financial Officer | Sale | −10,000 | $87.14 | $871K | 97,994 |
| 2026-06-25 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −15,000 | 359,857 | ||
| 2026-06-23 | Fairmount Funds Management LLC Director | Conversion | +666,680 | 4,684,781 | ||
| 2026-06-23 | Fairmount Funds Management LLC Director | Sale | −4,684,781 | $85.31 | $399.7M | 0 |
| 2026-06-23 | Fairmount Funds Management LLC Director | Conversion · Series B Preferred Stock | −16,667 | 0 | ||
| 2026-06-22 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −20,000 | $100.00 | $2.0M | 68,606 |
| 2026-06-03 | Sloan Sheldon Chief Medical Officer | Option exercise 10b5-1 | +8,333 | $27.46 | $229K | 8,333 |
| 2026-06-03 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −8,333 | $75.00 | $625K | 0 |
| 2026-06-03 | Sloan Sheldon Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,333 | 313,334 |
Page 4 of 11 · 213 trades